The standard approach begins with just 0.25 mg weekly, gradually climbing toward 2.4 mg over several months
actual results vary depending on dosage, duration of treatment, baseline levels, and individual factors like diet, exercise, weight loss, and genetics
Avoid placing your pen near heat sources such as stoves, radiators, or inside a hot car
One hypothesis is that we observed a greater induction of NRF2 through liver-specific Gclc deletion as compared to KEAP1 inhibition with CDDO-me because CDDO-me is a weaker inhibitor of NRF2-KEAP1 interaction compared to the ROS generated following GSH depletion
In this trial, MASH resolution without worsening of fibrosis was achieved in 4462% of participants receiving tirzepatide, compared with 10% in the placebo group, and fibrosis improvement of at least one stage without worsening of MASH occurred in up to 55% of tirzepatide-treated individuals versus only 30% with placebo [81]
[DOI] [PubMed] [Google Scholar] 25.Sun DX, Zhang FG, Geng YQ, Xi DS